respiratori
syncyti
viru
rsv
one
lead
caus
lower
respiratori
tract
infect
infant
immunoprophylaxi
antirsv
monoclon
antibodi
palivizumab
reduc
risk
rsvrelat
hospit
use
restrict
highrisk
infant
due
high
cost
studi
investig
genet
deliveri
antirsv
antibodi
neonat
mice
chimpanze
adenoviru
type
express
murin
form
palivizumab
provid
protect
rsv
intranas
intramuscular
administr
adult
mice
result
similar
level
antirsv
igg
serum
howev
intranas
administr
result
detect
level
antirsv
igg
bronchoalveolar
lavag
fluid
intranas
administr
provid
protect
subsequ
rsv
challeng
express
antirsv
antibodi
prolong
follow
intranas
administr
neonat
mice
protect
rsv
confirm
week
age
data
suggest
neonat
genet
deliveri
antirsv
antibodi
provid
protect
rsv
respiratori
syncyti
viru
rsv
one
lead
caus
lower
respiratori
tract
infect
children
high
morbid
mortal
especi
develop
countri
children
infect
first
year
life
infant
six
month
age
highest
risk
sever
diseas
especi
bronchopulmonari
dysplasia
cyanot
heart
diseas
despit
extens
effort
decad
effect
vaccin
treatment
rsv
immunoprophylaxi
neutral
monoclon
antibodi
palivizumab
avail
drug
prevent
infect
rsv
although
palivizumab
safe
welltoler
prophylact
use
use
limit
highrisk
infant
due
high
cost
need
monthli
intramuscular
inject
rsv
season
sinc
death
attribut
rsv
occur
lowincom
countri
expens
prophylaxi
afford
costeffect
strategi
need
spare
infant
risk
sever
rsv
diseas
genet
deliveri
neutral
antibodi
use
gene
transfer
vector
altern
strategi
achiev
sustain
express
neutral
antibodi
among
current
avail
viral
vector
adenoviru
ad
one
effici
gene
deliveri
system
preexist
immun
common
human
serotyp
hamper
use
human
nonhuman
primatederiv
ad
chimpanze
ad
serotyp
altern
vector
less
like
affect
preexist
immun
previous
report
neutral
antibodi
crossneutr
matern
immun
mice
vector
express
rsv
vaccin
antigen
protect
pup
rsv
infect
therefor
adopt
gene
transfer
vector
deliv
antirsv
neutral
antibodi
infant
expect
success
applic
presenc
matern
antihuman
ad
antibodi
antiad
immun
induc
vector
limit
longterm
express
transgen
thu
anoth
limit
ad
vector
howev
immun
toler
may
allow
longer
persist
vector
administ
neonat
neonat
immun
system
much
less
like
develop
vigor
immun
respons
transgen
protein
studi
administ
vector
express
antirsv
antibodi
neonat
mice
evalu
efficaci
deliv
antirsv
antibodi
protect
rsv
infect
balbc
mice
purchas
jackson
laboratori
bar
harbor
usa
hous
specif
pathogenfre
condit
bred
obtain
neonat
mice
adult
femal
balbc
mice
use
week
age
neonat
mice
use
h
birth
anim
studi
conduct
accord
protocol
review
approv
weill
cornel
institut
anim
care
use
committe
protocol
number
effort
made
minim
suffer
anim
rsv
strain
atcc
kindli
provid
ml
moor
emori
univers
atlanta
ga
usa
propag
cell
purifi
quantifi
describ
previous
recombin
ad
vector
use
studi
replic
defect
ad
vector
base
chimpanze
plasmid
ppangfp
kindli
provid
jm
wilson
univers
pennsylvania
philadelphia
pa
usa
digest
iceul
piscel
express
cassett
antirsv
antibodi
carri
cytomegaloviru
promoterenhanc
follow
cdna
encod
antirsv
light
chain
polioviru
intern
ribosom
entri
site
ire
antirsv
heavi
chain
polyadenyl
signal
insert
region
use
restrict
enzym
site
vector
green
fluoresc
protein
cdna
control
prokaryot
promot
lead
transgen
express
mammalian
cell
use
control
vector
propag
cell
purifi
centrifug
twice
cscl
gradient
previous
describ
particl
unit
pu
determin
spectrophotometr
confirm
express
antirsv
igg
vitro
supernat
cell
infect
separ
sdspage
nonreduc
reduc
condit
follow
transfer
polyvinyliden
difluorid
pvdf
membran
biorad
laboratori
hercul
ca
usa
murin
igg
detect
use
horseradish
peroxidas
hrp
conjug
sheep
antimous
igg
antibodi
sigma
st
loui
mo
usa
immobilon
western
chemiluminesc
hrp
substrat
emd
millipor
burlington
usa
supernat
mockinfect
cell
use
neg
control
mous
serum
obtain
week
follow
rsv
infect
use
posit
control
evalu
bind
antirsv
igg
rsv
rsv
pfuspot
blot
pvdf
membran
biorad
laboratori
hercul
ca
usa
develop
cultur
supernat
cell
infect
follow
sheep
antimous
iggperoxidas
antibodi
describ
puspot
blot
control
serial
dilut
supernat
cell
infect
h
incub
rsv
pfuml
h
c
ad
vero
cell
number
plaqu
quantifi
day
previous
describ
pu
dilut
pb
administ
intranas
intramuscularli
femal
balbc
mice
neonat
mice
receiv
either
pu
pu
vector
intranas
level
kinet
antirsv
igg
follow
administr
quantifi
serum
bronchoalveolar
lavag
bal
elisa
serial
dilut
serum
bal
ad
flatbottom
eiaria
plate
corn
corn
ny
usa
coat
human
antipalivizumab
clone
bioradantibodi
hercul
ca
usa
follow
pbst
blot
grade
blocker
biorad
laboratori
hercul
ca
usa
detect
perform
use
hrpconjug
sheep
antimous
igg
sigma
st
loui
mo
usa
pb
blot
grade
blocker
substrat
hydrogen
peroxidetetramethylbenzidin
r
system
minneapoli
mn
usa
absorb
nm
measur
titer
calcul
log
od
log
dilut
interpol
model
detect
cutoff
equal
background
absorb
halflif
calcul
formula
time
elaps
n
titer
week
n
titer
week
administr
mice
challeng
day
week
follow
ad
vector
administr
rsv
rsv
pfu
via
intranas
rout
four
day
challeng
rsv
quantifi
lung
homogen
plaqu
assay
viral
rna
quantifi
realtim
pcr
describ
previous
detect
rsv
viral
rna
primer
forward
revers
famlabel
taqman
mgb
probe
use
statist
analys
perform
use
oneway
anova
follow
twotail
unpair
student
ttest
statist
signific
determin
p
figur
gener
propag
cell
bind
abil
express
antirsv
igg
rsv
confirm
dot
blot
elisa
use
rsv
bind
cell
cultur
supernat
cell
infect
figur
figur
schema
chimpanze
adenoviru
type
vector
express
murin
antirespiratori
syncyti
viru
antibodi
gene
delet
replac
express
cassett
antirsv
antibodi
cdna
use
restrict
enzym
site
iceui
piscei
express
cassett
includ
cytomegaloviru
promot
p
cmv
follow
cdna
encod
antirsv
light
chain
lc
polioviru
intern
ribosom
entri
site
ire
antirsv
heavi
chain
hc
polyadenyl
signal
pa
confirm
express
murin
antirsv
igg
vitro
cell
infect
purifi
cell
cultur
supernat
assess
western
blot
analysi
figur
nonreduc
condit
complex
kda
correspond
size
complet
assembl
murin
igg
detect
bind
abil
express
antirsv
igg
rsv
confirm
dot
blot
elisa
use
rsv
bind
cell
cultur
supernat
cell
infect
figur
lane
plaquereduct
assay
show
dosedepend
neutral
rsv
antibodi
figur
lane
plaquereduct
assay
show
dosedepend
neutral
rsv
antibodi
figur
kinet
antirsv
igg
serum
adult
mice
follow
intranas
intramuscular
administr
show
antirsv
igg
titer
peak
one
week
follow
administr
gradual
decreas
nonspecif
respons
level
eight
week
figur
estim
halflif
day
although
titer
higher
follow
intramuscular
administr
kinet
antirsv
level
time
similar
two
rout
administr
contrast
antirsv
igg
bal
one
week
detect
follow
intranas
administr
figur
kinet
antirsv
igg
serum
adult
mice
follow
intranas
intramuscular
administr
show
antirsv
igg
titer
peak
one
week
follow
administr
gradual
decreas
nonspecif
respons
level
eight
week
figur
estim
halflif
day
although
titer
higher
follow
intramuscular
administr
kinet
antirsv
level
time
similar
two
rout
administr
contrast
antirsv
igg
bal
one
week
detect
follow
intranas
administr
figur
vaccin
x
lane
plaquereduct
assay
show
dosedepend
neutral
rsv
antibodi
figur
kinet
antirsv
igg
serum
adult
mice
follow
intranas
intramuscular
administr
show
antirsv
igg
titer
peak
one
week
follow
administr
gradual
decreas
nonspecif
respons
level
eight
week
figur
estim
halflif
day
although
titer
higher
follow
intramuscular
administr
kinet
antirsv
level
time
similar
two
rout
administr
contrast
antirsv
igg
bal
one
week
detect
follow
intranas
administr
figur
evalu
deliv
suffici
antibodi
protect
rsv
infect
pb
control
intranas
administ
eightweekold
femal
balbc
mice
follow
rsv
infect
three
day
later
rsv
viral
load
lung
mice
receiv
lower
detect
level
compar
mice
receiv
figur
p
likewis
rsv
viral
genom
also
decreas
mice
receiv
compar
figur
p
suggest
intranas
administr
provid
protect
rsv
infect
adult
mice
vaccin
x
evalu
deliv
suffici
antibodi
protect
rsv
infect
pb
control
intranas
administ
eightweekold
femal
balbc
mice
follow
rsv
infect
three
day
later
rsv
viral
load
lung
mice
receiv
lower
detect
level
compar
mice
receiv
figur
p
likewis
rsv
viral
genom
also
decreas
mice
receiv
compar
figur
p
suggest
intranas
administr
provid
protect
rsv
infect
adult
mice
evalu
administ
neonat
mice
lead
protect
rsv
intranas
administ
onedayold
mice
antirsv
igg
detect
mice
receiv
four
six
week
age
figur
kinet
antirsv
igg
serum
neonat
mice
four
week
age
follow
intranas
administr
show
titer
highest
four
week
gradual
decreas
stay
detect
level
nine
week
figur
serum
antirsv
igg
titer
also
detect
level
week
follow
intranas
administr
mice
receiv
higher
dose
tend
higher
antirsv
igg
titer
particularli
lung
homogen
supernat
figur
importantli
challeng
rsv
six
week
age
show
reduct
viral
load
mice
receiv
undetect
rsv
level
three
five
mice
compar
mice
receiv
receiv
ad
vector
figur
protect
rsv
also
evalu
later
time
point
antirsv
igg
express
confirm
mice
receiv
four
eight
week
age
figur
challeng
rsv
week
age
also
show
reduct
viral
load
three
four
mice
receiv
compar
mice
receiv
receiv
ad
vector
figur
data
suggest
administr
neonat
mice
lead
protect
rsv
prolong
protect
immun
compar
adult
mice
provid
evalu
administ
neonat
mice
lead
protect
rsv
intranas
administ
onedayold
mice
antirsv
igg
detect
mice
receiv
four
six
week
age
figur
kinet
antirsv
igg
serum
neonat
mice
four
week
age
follow
intranas
administr
show
titer
highest
four
week
gradual
decreas
stay
detect
level
nine
week
figur
serum
antirsv
igg
titer
also
detect
level
week
follow
intranas
administr
mice
receiv
higher
dose
tend
higher
antirsv
igg
titer
particularli
lung
homogen
supernat
figur
importantli
challeng
rsv
six
week
age
show
reduct
viral
load
mice
receiv
undetect
rsv
level
three
five
mice
compar
mice
receiv
receiv
ad
vector
figur
protect
rsv
also
evalu
later
time
point
antirsv
igg
express
confirm
mice
receiv
four
eight
week
age
figur
challeng
rsv
week
age
also
show
reduct
viral
load
three
four
mice
receiv
compar
mice
receiv
receiv
ad
vector
figur
data
suggest
administr
neonat
mice
lead
protect
rsv
prolong
protect
immun
compar
adult
mice
provid
studi
show
intranas
administr
could
provid
protect
rsv
infect
administr
rout
ad
vector
may
greatli
contribut
effici
local
deliveri
airway
intraven
administr
palivizumab
shown
effect
rodent
human
effect
reduc
lung
rsv
load
lung
cotton
rat
detect
human
nasal
wash
known
intramuscularli
inject
palivizumab
slowli
absorb
maximum
serum
concentr
reach
three
five
day
kinet
lung
airway
level
less
wellknown
data
show
antirsv
igg
detect
bal
intranas
administr
intramuscular
administr
time
peak
serum
igg
level
one
week
intranas
administr
rout
may
advantag
product
neutral
antibodi
directli
respiratori
mucos
cell
primari
target
rsv
futur
studi
examin
cellular
sourc
antibodi
within
respiratori
mucosa
includ
analys
noseassoci
lymphoid
tissu
nalt
immun
cell
immun
respons
respiratori
tract
alter
prior
viral
infect
recent
studi
reveal
nasal
prime
virus
influenc
lung
immun
induc
protect
immun
heterolog
viral
infect
data
adult
mice
show
protect
rsv
also
mice
receiv
control
vector
figur
although
protect
subsequ
rsv
infect
much
greater
mice
receiv
vector
seem
prime
effect
lung
immun
neonat
adapt
immun
respons
show
great
deal
variabl
rang
nonrespons
fulli
matur
function
shown
newborn
mice
toler
ad
vector
repeat
administr
ad
vector
could
possibl
thu
immun
toler
expect
vector
administ
neonat
administr
onedayold
mice
result
prolong
antibodi
express
compar
adult
mice
anoth
potenti
advantag
neonat
gene
deliveri
higher
vector
particlestocel
ratio
requir
lower
rel
dose
addit
ad
vector
deliveri
seem
effici
neonat
lung
compar
adult
lung
data
show
serum
antirsv
igg
titer
higher
neonat
administr
compar
adult
administr
albeit
dose
reduc
burden
diseas
caus
rsv
strong
consensu
focu
place
children
first
six
month
life
risk
sever
rsvassoci
respiratori
figur
protect
rsv
infect
follow
administr
neonat
mice
pu
intranas
administ
balbc
mice
follow
rsv
pfu
challeng
week
age
antirsv
igg
titer
serum
rsv
challeng
serum
collect
week
titer
measur
elisa
data
shown
mean
sem
b
rsv
viral
load
lung
day
rsv
challeng
plaqu
assay
data
shown
mean
sem
denot
p
p
respect
studi
show
intranas
administr
could
provid
protect
rsv
infect
administr
rout
ad
vector
may
greatli
contribut
effici
local
deliveri
airway
intraven
administr
palivizumab
shown
effect
rodent
human
effect
reduc
lung
rsv
load
lung
cotton
rat
detect
human
nasal
wash
known
intramuscularli
inject
palivizumab
slowli
absorb
maximum
serum
concentr
reach
three
five
day
kinet
lung
airway
level
less
wellknown
data
show
antirsv
igg
detect
bal
intranas
administr
intramuscular
administr
time
peak
serum
igg
level
one
week
intranas
administr
rout
may
advantag
product
neutral
antibodi
directli
respiratori
mucos
cell
primari
target
rsv
futur
studi
examin
cellular
sourc
antibodi
within
respiratori
mucosa
includ
analys
noseassoci
lymphoid
tissu
nalt
immun
cell
immun
respons
respiratori
tract
alter
prior
viral
infect
recent
studi
reveal
nasal
prime
virus
influenc
lung
immun
induc
protect
immun
heterolog
viral
infect
data
adult
mice
show
protect
rsv
also
mice
receiv
control
vector
figur
although
protect
subsequ
rsv
infect
much
greater
mice
receiv
vector
seem
prime
effect
lung
immun
neonat
adapt
immun
respons
show
great
deal
variabl
rang
nonrespons
fulli
matur
function
shown
newborn
mice
toler
ad
vector
repeat
administr
ad
vector
could
possibl
thu
immun
toler
expect
vector
administ
neonat
administr
onedayold
mice
result
prolong
antibodi
express
compar
adult
mice
anoth
potenti
advantag
neonat
gene
deliveri
higher
vector
particlestocel
ratio
requir
lower
rel
dose
addit
ad
vector
deliveri
seem
effici
neonat
lung
compar
adult
lung
data
show
serum
antirsv
igg
titer
higher
neonat
administr
compar
adult
administr
albeit
dose
reduc
burden
diseas
caus
rsv
strong
consensu
focu
place
children
first
six
month
life
risk
sever
rsvassoci
respiratori
diseas
highest
immun
provid
protect
immun
last
throughout
vulner
period
would
ideal
strategi
protect
children
rsv
infect
focus
passiv
immun
studi
combin
passiv
immun
activ
immun
attract
strategi
provid
complet
protect
immun
throughout
vulner
period
sinc
matur
respons
vaccin
also
expect
neonat
immun
system
simultan
administr
carri
antirsv
neutral
antibodi
rsv
vaccin
antigen
may
provid
passiv
activ
immun
appropri
vaccin
antigen
overlap
antigen
site
palivizumab
would
requir
make
strategi
success
includ
wildtyp
rsv
rsv
vaccin
control
studi
sinc
primari
interest
determin
genet
deliveri
antirsv
antibodi
vector
effect
neonat
mice
use
control
vector
without
transgen
express
futur
studi
includ
wildtyp
rsv
vaccin
control
evalu
effect
vector
strategi
even
wildtyp
rsv
realist
vaccin
altern
neonat
halflif
deliv
antibodi
studi
day
compat
known
halflif
palivizumab
prolong
express
seen
vector
administ
neonat
mice
could
estim
halflif
antibodi
sinc
serial
collect
neonat
serum
feasibl
sever
explan
possibl
prolong
express
antibodi
may
longer
halflif
adult
mice
uniqu
immunolog
properti
neonat
mice
effici
gene
deliveri
may
greater
due
higher
suscept
ad
neonat
lung
recent
develop
new
antirsv
monoclon
antibodi
went
toward
prolong
serum
halflif
amino
acid
modif
made
possibl
extend
serum
halflif
antibodi
modifi
express
cassett
deliv
effici
antirsv
monoclon
antibodi
extend
halflif
may
enabl
longterm
protect
rsv
summari
data
show
intranas
administr
neonat
mice
provid
prolong
express
antirsv
antibodi
protect
rsv
infect
neonat
immun
respons
mainli
studi
mice
indic
similar
situat
true
human
earli
life
demonstr
potenti
neonat
genet
deliveri
nonhuman
primatebas
ad
vector
could
effici
deliv
antirsv
neutral
antibodi
neonat
lung
could
provid
protect
rsv
supplementari
materi
follow
avail
onlin
http
figur
assess
antirsv
igg
express
neonat
mice
figur
protect
rsv
week
follow
administr
neonat
mice
author
contribut
sw
conceptu
studi
rg
ww
perform
experiment
procedur
supervis
experi
rg
analyz
data
wrote
manuscript
sw
review
edit
manuscript
fund
research
fund
nation
institut
health
grant
number
sw
